Loss of Heterozygosity at the CYP2D6 Locus in Breast Cancer: Implications for Tamoxifen Pharmacogenetic Studies

Johnson Julie A.; Hamadeh Issam S.; Langaee Taimour Y.

首页> 外文期刊>Journal of the National Cancer Institute >Loss of Heterozygosity at the CYP2D6 Locus in Breast Cancer: Implications for Tamoxifen Pharmacogenetic Studies

【24h】

Loss of Heterozygosity at the CYP2D6 Locus in Breast Cancer: Implications for Tamoxifen Pharmacogenetic Studies

机译：CYP2D6位点在乳腺癌中杂合性的损失：对他莫昔芬药理学研究的意义。

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Journal of the National Cancer Institute》 |2015年第2期|共1页
作者
Johnson Julie A.; Hamadeh Issam S.; Langaee Taimour Y.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词
入库时间 2022-08-19 04:52:08

相似文献

外文文献
中文文献
专利

1. Loss of Heterozygosity at the CYP2D6 Locus in Breast Cancer: Implications for Tamoxifen Pharmacogenetic Studies [J] . Johnson Julie A., Hamadeh Issam S., Langaee Taimour Y. Journal of the National Cancer Institute . 2015,第2期

机译：CYP2D6位点在乳腺癌中杂合性的损失：对他莫昔芬药理学研究的意义。
2. RE: Loss of Heterozygosity at the CYP2D6 Locus in Breast Cancer: Implications for Germline Pharmacogenetic Studies [J] . Rae James M., Leyland-Jones Brian, Regan Meredith, Journal of the National Cancer Institute . 2015,第5期

机译：RE：CYP2D6基因位点在乳腺癌中的杂合性丧失：对生殖细胞药物遗传学研究的意义
3. Loss of Heterozygosity at the CYP2D6 Locus in Breast Cancer: Implications for Germline Pharmacogenetic Studies [J] . Goetz Matthew P., Sun James X., Suman Vera J., Journal of the National Cancer Institute . 2015,第2期

机译：CYP2D6位点在乳腺癌中杂合性的损失：对生殖细胞药理学研究的意义。
4. Study on Molecular Docking of Red Betel (Piper Crocatum Ruiz Pav.) Active Compound and Tamoxifen Drug as an Inhibitor of Estrogen Receptor-α (ER-α) that Plays a Role in Breast Cancer [C] . Siti Imroatul Maslikah, Sri Rahayu Lestari, Nursasi Handayani, International Conference on Life Sciences and Technology . 2020

机译：红色槟榔（吹笛茶叶ruiz＆pav.）活性化合物和三氧化物药物作为发挥乳腺癌作用的雌激素受体-α（ER-α）抑制剂的研究
5. Integrated mapping and gene analysis in regions showing loss of heterozygosity in human breast cancer in the short arm of Chromosome 1. [D] . Baptista, Pedro M.R.V. 2000

机译：在染色体1的短臂中显示人类乳腺癌杂合性缺失的区域中的综合作图和基因分析。
6. Loss of Heterozygosity at the CYP2D6 Locus in Breast Cancer: Implications for Germline Pharmacogenetic Studies [O] . Matthew P. Goetz, James X. Sun, Vera J. Suman, -1

机译：CYP2D6位点在乳腺癌中杂合性的损失：对生殖细胞药理学研究的意义。
7. Loss of Heterozygosity at the CYP2D6 Locus in Breast Cancer: Implications for Tamoxifen Pharmacogenetic Studies [O] . J. A. Johnson, I. S. Hamadeh, T. Y. Langaee 2015

机译：乳腺癌CYP2D6基因座的杂合性丧失：对他莫昔芬药物发生研究的影响
8. Systematic Reviews on Selected Pharmacogenetic Tests for Cancer Treatment: CYP2D6 for Tamoxifen in Breast Cancer, KRAS for anti-EGFR antibodies in Colorectal Cancer, and BCR-ABL1 for Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia. Technology Assessment Report [R] . Terasawa, T., Dahabreh, I., Castaldi, P. J., 2010

机译：针对癌症治疗的选定药物遗传学测试的系统评价：CYp2D6用于乳腺癌中的他莫昔芬，KRas用于结肠直肠癌中的抗EGFR抗体，以及BCR-aBL1用于慢性髓性白血病中的酪氨酸激酶抑制剂。技术评估报告

Loss of Heterozygosity at the CYP2D6 Locus in Breast Cancer: Implications for Tamoxifen Pharmacogenetic Studies

著录项

相似文献

相关主题

期刊订阅